Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
Publication Type:
Journal Article
Authors:
Kowdley, K.V.;
Gordon, S.C.;
K R Reddy;
Rossaro, L.;
Bernstein, D.E.;
E J Lawitz;
Shiffman, M.L.;
E R Schiff;
Ghalib, R.;
Ryan, M.;
Rustgi, V.;
Chojkier, M.;
Herring, R.;
A M Di Bisceglie;
Pockros, P.J.;
Subramanian, G.M.;
An, D.;
E. S. Svarovskaia;
Hyland, R.H.;
Pang, P.S.;
Symonds, W.T.;
J G McHutchison;
Muir, A.J.;
Pound, D.;
Fried, M.W.Source:
N Engl J Med, Volume 370, Issue 20, p.1879-1888 (2014)
Keywords:
California,
chronic HCV,
Cities,
Disease,
Genotype,
genotype 1,
HCV,
Health,
hepatitis,
Hepatitis C,
hepatitis C virus,
Infection,
Liver,
Liver Diseases,
Medicine,
methods,
North Carolina,
NS5A inhibitor,
Patients,
Philadelphia,
Research,
Research Support,
Ribavirin,
sofosbuvir,
sustained virologic response,
Texas,
therapy,
treatment
